key drawbacks of DPP-4 inhibitors

DPP-4 inhibitors like Sitagliptin and Vildagliptin are used by patients over a long period. Patients using these drugs would benefit from understanding their side effect profiles. This article is an attempt to provide that information.

Risk: There have been reports suggesting an increased risk of acute pancreatitis with the use of DPP-4 inhibitors. Patients should be monitored for signs and symptoms of pancreatitis, such as persistent severe abdominal pain.

Joint Pain: Some patients may experience severe and disabling joint pain. Physicians should consider discontinuing the medication if patients report severe joint pain.

Heart Failure: Certain DPP-4 inhibitors, particularly saxagliptin and alogliptin, have been associated with an increased risk of heart failure, especially in patients with existing heart or kidney disease.

Hypersensitivity Reactions: DPP-4 inhibitors can cause serious allergic reactions, including anaphylaxis, angioedema, and exfoliative skin conditions. It is important to discontinue the drug if serious hypersensitivity reactions occur.

Hypoglycemia Risk: Although DPP-4 inhibitors themselves have a low risk of hypoglycemia, when used in combination with other glucose-lowering agents like insulin or sulfonylureas, the risk of hypoglycemia can increase.

Renal Impairment: Dose adjustment is often required for patients with renal impairment. Physicians should assess renal function before and during treatment.

Infections: There is some evidence suggesting an increased risk of nasopharyngitis and upper respiratory tract infections. Monitoring for signs of infection and educating patients about this potential side effect is important.

Long-Term Safety: The long-term safety profile of DPP-4 inhibitors is still being studied. Physicians should stay updated on the latest research and guidelines.

Given these potential drawbacks, it is crucial to thoroughly evaluate each patient's individual risk factors and monitor them closely during treatment with DPP-4 inhibitors.

Regards,

Amit Katoch,

JAKSTAR PHARMA